Rosetta Exosome Co., Ltd.

12:00 PM - 12:15 PM (PDT), Thursday, June 16, 2022
Rosetta Exosome is a biopharmaceutical company based on exosome-based therapeutics. We have developed a novel cancer immunotherapy against different cancer types (OncoLEx: OncoLytic Exosome) and vaccina delivery system using microbiome-derived exosomes. In addition, we have developed drug delivery systems and therapeutics based on engineered mammalian exosome or exosome mimetic nanovesicles. Our company owns 22 registered patents with 424 registered claims around the world. By combining bacterial fermentation and our proprietary exosome isolation and characterization technologies (ExoLutE® platform technology), we have developed a very cost effective process for large-scale production of high-quality bacterial exosomes. These universal effectiveness against human diverse cancer types and cost-effective large-scale production of OncoLEx should be significant advantages over other cancer immunotherapies such as immune check point antibodies and mammalian exosomes.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
REX101: microbiome-derived exosome-based cancer immunotherapy
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Rosetta Exosome Co., Ltd.